SHERRY WALLMARKER: Open Payments
NPI 1578946356 · DALTON, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,788 in 128 payments from 16 companies in 2025. Trend: 2023 $1,785 · 2024 $2,028 · 2025 $2,788
Food & beverage: $2,678Education: $109
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 40 | $733 |
| Madrigal Pharmaceuticals | 13 | $454 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 20 | $425 |
| Janssen Biotech, Inc. | 16 | $339 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $207 |
| Gilead Sciences, Inc. | 6 | $158 |
| Aimmune Therapeutics, Inc. | 6 | $142 |
| QOL Medical, LLC | 3 | $86 |
| Phathom Pharmaceuticals, Inc. | 5 | $83 |
| GENZYME CORPORATION | 2 | $42 |
Products named: REZDIFFRA, XIFAXAN, TREMFYA, LINZESS, RINVOQ, ENTYVIO, CREON, ZENPEP.
Industry payments across GA — which companies pay providers there.
